Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 5/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | QSOX1 | O00391 | 1/20 | 1.00 |
| ▸ | RGS12 | O14924 | 1/20 | 1.00 |
| ▸ | PMM2 | O15305 | 1/20 | 1.00 |
| ▸ | PLIN1 | O60240 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | BBOX1 | O75936 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYBB | P04839 | 1/20 | 1.00 |
| ▸ | BCHE | P06276 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | G6PD | P11413 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ebselen SCHEMBL33829 | 1.00 | METAP2 (1.00) | METAP2KDM4EMEN1QSOX1RGS12 | |
| Ebselen SCHEMBL4406056 | 1.00 | METAP2 (1.00) | METAP2KDM4EMEN1QSOX1RGS12 | |
| Ebselen SCHEMBL19064566 | 0.98 | METAP2 (0.96) | METAP2KDM4EMEN1QSOX1RGS12 | |
| Ebselen SCHEMBL20678555 | 0.98 | METAP2 (0.96) | METAP2KDM4EMEN1QSOX1RGS12 | |
| Ebselen SCHEMBL20477111 | 0.98 | METAP2 (0.96) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL193047 | 0.89 | METAP2 (0.79) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL28783439 | 0.87 | METAP2 (0.77) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL10501092 | 0.85 | METAP2 (1.00) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL10502294 | 0.85 | METAP2 (1.00) | METAP2KDM4EMEN1QSOX1RGS12 | |
| SCHEMBL1354655 | 0.85 | METAP2 (0.74) | METAP2KDM4EMEN1QSOX1RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ASS FRANCAISE CONTRE LES MYOPATHIES (FR) | 2026-01-01 | — | — | US | claimed |
| EP-4630816-A1 | A METHOD COMPRISING PERFORMING ON A SINGLE-ANALYTE ARRAY AT LEAST 50 CYCLES OF A PROCESS | Nautilus Subsidiary, Inc. (US) | 2025-10-15 | — | — | EP | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4551214-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | Association Française contre les Myopathies (FR) | 2025-05-14 | — | — | EP | claimed |
| CN-119768165-A | Use of ebselen or one of its derivatives for the treatment of mitochondrial conditions or dysfunctions | 法国抗肌病协会 | 2025-04-04 | — | — | CN | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| WO-2024008788-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ASSOCIATION FRANCAISE CONTRE LES MYOPATHIES (FR) | 2024-01-11 | — | — | WO | claimed |
| US-11464784-B2 | Inhibition of aminocylase 3 (AA3) in the treatment of cancer | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-10-11 | — | — | US | claimed |
| WO-2022167778-A1 | EBSELEN AS ADENOSINE RECEPTOR MODULATOR | HAIKU THERAPEUTICS LTD (GB) | 2022-08-11 | — | — | WO | claimed |
| US-20260108533-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION | AZURA OPHTHALMICS LTD (IL) | 2026-04-23 | — | — | US | disclosed |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | ALUME BIOSCIENCES, INC. (US) | 2026-01-27 | — | — | US | disclosed |
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ASS FRANCAISE CONTRE LES MYOPATHIES (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20250352482-A1 | AMORPHOUS DOSAGE FORM CONTAINING EBSELEN | SOUND PHARMACEUTICALS INC (US) | 2025-11-20 | — | — | US | disclosed |
| EP-4634285-A1 | INHIBITION OF PHOTON PHENOMENA ON SINGLE MOLECULE ARRAYS | Nautilus Subsidiary, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| CN-114380772-A | Selenium-containing compound and application thereof | 深圳福山生物科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022079246-A1 | NLRP3 ACTIVATORS FOR USE IN THE TREATMENT OF INFECTIOUS DISEASES OR CANCER BY ACTIVATING NLRP3 INFLAMMASOME | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2022-04-21 | — | — | WO | disclosed |
| EP-3952881-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CONTACT LENS DISCOMFORT | Azura Ophthalmics Ltd. (IL) | 2022-02-16 | — | — | EP | disclosed |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2022-02-10 | — | — | US | disclosed |
| CN-114025759-A | Compounds and methods for treating ocular diseases | 阿祖拉眼科有限公司 | 2022-02-08 | — | — | CN | disclosed |
| CN-114007625-A | Compounds and methods for treating ocular diseases | 阿祖拉眼科有限公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000645-A1 | USE OF EBSELEN OR ONE OF THE DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL PATHOLOGIES OR DYSFUNCTIONS | ERAL1, MT-CO3, GFM1 | METAP2 1071/4885KDM4E 4164/4885MEN1 1710/4885 |
| US-12533425-B2 | Methods and systems using peptides for targeting and mapping human nerves in image guided surgery, diagnostics and therapeutic delivery | NGLY1, VGF, GAP43 | METAP2 2118/4885KDM4E 4602/4885MEN1 1105/4885 |
| US-11464784-B2 | Inhibition of aminocylase 3 (AA3) in the treatment of cancer | PLAAT3, HCCS, LAP3 | METAP2 164/4885KDM4E 523/4885MEN1 4787/4885 |
| US-20220040095-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | METAP2 983/4885KDM4E 4174/4885MEN1 629/4885 |
| US-20250352482-A1 | AMORPHOUS DOSAGE FORM CONTAINING EBSELEN | SBDS, RPS27L, CYP2C9 | METAP2 2006/4885KDM4E 3163/4885MEN1 3204/4885 |
| US-20260108533-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MEIBOMIAN GLAND DYSFUNCTION | SCLY, PLA2G2D, STS | METAP2 273/4885KDM4E 3361/4885MEN1 2387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.